Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2
Open Access
- 22 August 2022
- journal article
- research article
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-9
Abstract
Antidepressants have previously been associated with better outcomes in patients hospitalized with COVID-19, but their effect on clinical deterioration among ambulatory patients has not been fully explored. The objective of this study was to assess whether antidepressant exposure was associated with reduced emergency department (ED) or hospital visits among ambulatory patients with SARS-CoV-2 infection. This retrospective cohort study included adult patients (N = 25 034) with a positive SARS-CoV-2 test performed in a non-hospital setting. Logistic regression analyses tested associations between home use of antidepressant medications and a composite outcome of ED visitation or hospital admission within 30 days. Secondary exposures included individual antidepressants and antidepressants with functional inhibition of acid sphingomyelinase (FIASMA) activity. Patients with antidepressant exposure were less likely to experience the primary composite outcome compared to patients without antidepressant exposure (adjusted odds ratio [aOR] 0.89, 95% CI 0.79–0.99, p = 0.04). This association was only observed with daily doses of at least 20 mg fluoxetine-equivalent (aOR 0.87, 95% CI 0.77–0.99, p = 0.04), but not with daily doses lower than 20 mg fluoxetine-equivalent (aOR 0.94, 95% CI 0.80–1.11, p = 0.48). In exploratory secondary analyses, the outcome incidence was also reduced with exposure to selective serotonin reuptake inhibitors (aOR 0.87, 95% CI 0.75–0.99, p = 0.04), bupropion (aOR 0.70, 95% CI 0.55–0.90, p = 0.005), and FIASMA antidepressant drugs (aOR 0.87, 95% CI 0.77–0.99, p = 0.03). Antidepressant exposure was associated with a reduced incidence of emergency department visitation or hospital admission among SARS-CoV-2 positive patients, in a dose-dependent manner. These data support the FIASMA model of antidepressants’ effects against COVID-19.Keywords
Funding Information
- Foundation for Anesthesia Education and Research (MRTG08152020FRITZ)
- U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002345, UL1TR002345)
- U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences
This publication has 64 references indexed in Scilit:
- Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trialsJournal of Affective Disorders, 2015
- Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cellsEuropean Journal of Pharmacology, 2014
- Identification of Novel Functional Inhibitors of Acid SphingomyelinasePLOS ONE, 2011
- Persistence and compliance to antidepressant treatment in patients with depression: A chart reviewBMC Psychiatry, 2009
- A Modification of the Elixhauser Comorbidity Measures Into a Point System for Hospital Death Using Administrative DataMedical Care, 2009
- Possible involvement of sigma‐1 receptors in the anti‐immobility action of bupropion, a dopamine reuptake inhibitorFundamental & Clinical Pharmacology, 2008
- Identification of New Functional Inhibitors of Acid Sphingomyelinase Using a Structure−Property−Activity Relation ModelJournal of Medicinal Chemistry, 2007
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- 5HT2 and 5HT3 receptors' contribution to modeling of post-serotonin respiratory pattern in catsLife Sciences, 2004
- Paroxetine decreases platelet serotonin storage and platelet function in human beingsClinical Pharmacology & Therapeutics, 2000